Skye Bioscience, Inc. Common Stock (SKYE) is a publicly traded Healthcare sector company. As of November 10, 2026, SKYE trades at $0.77 with a market cap of $4.38M and a P/E ratio of -1.17. SKYE moved +11.59% today. Year to date, SKYE is -89.05%; over the trailing twelve months it is -93.72%. Its 52-week range spans $0.51 to $46.00. Rallies surfaces SKYE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5AM Partners VII reports $238,903 Skye Bioscience common stock disposal: 5AM Partners VII reported selling 27,612 Skye Bioscience shares at $1.65 on Sept. 22, 2026, and disposing of 119,379 shares at $1.61 the next day. It continued to indirectly own 981,269 shares held by 5AM Ventures VII.
| Metric | Value |
|---|---|
| Price | $0.77 |
| Market Cap | $4.38M |
| P/E Ratio | -1.17 |
| EPS | $-1.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.00 |
| 52-Week Low | $0.51 |
| Volume | 1.48M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-55.92M |
| Gross Margin | 0.00% |
SKYE analyst coverage data. Average price target: $0.00.